Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
45 Results for "
CK II
" in MedChemExpress (MCE) Product Catalog:
Products (45)
45 Results for "CK II" in MCE Product Catalog:
15
15 Publications Verification
Synonyms: GSK-3β Inhibitor I; NP 01139
TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.
9
9 Cited Publications
Synonyms: CK2 Inhibitor; Casein kinase II Inhibitor
Target:
Research Areas:
DMAT is a potent and specific CK2 inhibitor with an IC50 value of 130 nM.
1
1 Cited Publications
Cat. No.: HY-W011109
CAS No.: 1177141-67-1
Target:
Research Areas:
CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases .
1
1 Cited Publications
Cat. No.: HY-133028
CAS No.: 120615-25-0
Target:
Research Areas:
CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases .
1
1 Cited Publications
Target:
Research Areas:
TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .
1
1 Cited Publications
Cat. No.: HY-P76263
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Casein kinase II subunit alpha; CK II alpha; CSNK2A1; CK2A1
Species:
Source:
Cat. No.: HY-P3921
CAS No.: 95651-74-4
Target:
Research Areas:
Cat. No.: HY-103384
CAS No.: 905105-89-7
Target:
Research Areas:
TMCB is a selective, ATP-competitive CK2 (casein kinase II) inhibitor with distinct Ki values of 83 nM and 21 nM for the two different catalytic CK2 subunits α and α', respectively .
Cat. No.: HY-120036
CAS No.: 153150-84-6
Target:
Research Areas:
Tyrphostin AG1112 is a potent inhibitors of CK II. Tyrphostin AG1112 inhibits p210 bcr-abl tyrosine kinase, with IC50 values of 2, 15, 20 μM in p210 bcr-abl, EGFR and PDGFR cells, respectively .
Cat. No.: HY-RS03251
Target:
Research Areas:
CSNK2A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CSNK2A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-11012R
CAS No.: 327036-89-5
Synonyms: GSK-3β Inhibitor I (Standard); NP 01139 (Standard)
Target:
Research Areas:
TDZD-8 (Standard) is the analytical standard of TDZD-8. This product is intended for research and analytical applications. TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.
Cat. No.: HY-111093
CAS No.: 926319-75-7
Target:
Research Areas:
Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases .
Cat. No.: HY-146138
CAS No.: 2492382-37-1
Research Areas:
EGFR-IN-57 (Compound 25a) is a potent, orally active EGFR-TK inhibitor with an IC50 of 0.054 µM. EGFR-IN-57 also inhibits VEGFR-2, CK2α, topoisomerase IIβ and tubulin polymerization with IC50 values of 0.087, 0.171, 0.13 and 3.61 µM, respectively. EGFR-IN-57 induces cell cycle arrest at G2/M and pre-G1 phases. EGFR-IN-57 induces cancer cell apoptosis .
Cat. No.: HY-P76825
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Casein kinase II subunit alpha; CK II alpha; CSNK2A1; CK2A1
Species:
Source:
Cat. No.: HY-P76826
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: Casein kinase II subunit alpha; CK II alpha; CSNK2A1; CK2A1
Species:
Source:
Cat. No.: HY-P3921A
Target:
Research Areas:
Cat. No.: HY-P76296
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Casein kinase II subunit alpha'; CK II alpha'; CSNK2A2; CK2A2
Species:
Source:
Cat. No.: HY-P76297
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Casein kinase II subunit alpha'; CK II alpha'; CSNK2A2; CK2A2
Species:
Source:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
